Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: VeloSpeed who wrote (1217)	5/17/1999 11:23:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 1826

From the WSJ interactive, not new news DJ MGI Pharm Drug Study -2:Involved Up To 30 Patients Dow Jones Newswires MINNEAPOLIS -- MGI Pharma Inc.'s (MOGN) MGI 114 cancer-fighting drug showed "significant antitumor activity" in a recently released phase II clinical study. In a press release Monday, the pharmaceutical company said it is "encouraged" by the activity of MGI 114 against hormone-resistant prostate tumors, and as a result of early positive responses it expanded the trial late last year. The study, which involves patients with prostate tumors that have stopped responding to hormone therapies, was designed to assess the antitumor activity of the drug measured by a decrease in serum prostate specific antigen in up to 30 patients. A company spokeswoman said 21 of the 30 patients were "evaluable" for serum prostate specific antigen, and 76% of those 21 have shown stable or decreasing levels of the antigen. The spokeswoman said the company intends to have 30 evaluable patients in the study, which could mean reaching a total enrollment of 40 or 50 in the ongoing study. MGI 114 is the lead member of the company's group of new chemotherapy agents called acylfulvenes, which the company said appear to have potential advantages over existing cancer therapies. The company said in previous studies MGI 114 has "demonstrated activity against" a variety of tumor types, and clinical studies are underway focusing on kidney, prostate, pancreatic, ovarian, colon and rectal and non-small cell lung cancers. In addition, a pediatric study is underway and a phase I study in leukemia patients is planned. Nasdaq-listed shares of MGI Pharma last traded down 1 1/16, or 8.8%, at 11 on composite volume of 65,000 shares. Average daily volume is 67,030 shares Jim